Role of MRI in osteosarcoma for evaluation and prediction of chemotherapy response: correlation with histological necrosis

Bajpai, Jaya; Gamnagatti, Shivanand; Kumar, Rakesh; Sreenivas, Vishnubhatla; Sharma, Mehar Chand; Khan, Shah Alam; Rastogi, Shishir; Malhotra, Arun; Safaya, Rajni; Bakhshi, Sameer

doi:10.1007/s00247-010-1876-3

Cited by 97 publications

(89 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, there have been conflicting results. Other studies have not identified a significant association between ADC value and tumor necrosis (23,26,28). Therefore, the predictive value of ADC remained undetermined.…”

Section: Discussionmentioning

confidence: 94%

“…Using the predefined electric literature databases, we identified 80 potentially eligible articles, of which 72 were excluded due to duplication or after reviewing the article title and abstract. Subsequently, 3 articles were excluded after reviewing the whole article (23)(24)(25). Five articles with 106 patients who fulfilled all of the inclusion criteria were selected for the meta-analysis (Table I) (26)(27)(28)(29)(30).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Value of diffusion-weighted imaging for evaluating chemotherapy response in osteosarcoma: A meta-analysis

Kubo

Furuta

Johan

et al. 2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. The histological examination of the tumor necrosis upon surgery remains the most reliable prognostic factor for osteosarcoma. However, the detection of more early prognostic factors is desirable in order to increase the survival rates and decrease the risk rates for iatrogenic toxicity. The purpose of the current systematic review and meta-analysis was to provide an up-to-date summary of the role of diffusion-weighted imaging (DWI) for the preoperative assessment of the chemotherapy response in osteosarcoma. Articles evaluating DWI for the preoperative assessment of the chemotherapy response of osteosarcoma were systematically searched for in four electronic literature databases. The mean difference in apparent diffusion coefficient (ADC) following neoadjuvant chemotherapy between good and poor histological responders was assessed in 5 studies. The mean difference in the ADC ratio (the percentage change in ADC between post-neoadjuvant and pre-neoadjuvant chemotherapy) reported in 3 studies was also assessed. Five articles with 106 patients fulfilled all of the inclusion criteria for the meta-analysis. Significant mean differences were found between good and poor responders in the ADC in the 5 studies (P=0.03) and the ADC ratio in the 3 studies (P<0.00001). The good responders demonstrated a higher ADC and a higher ADC ratio than the poor responders. DWI performed with ADC values was useful for predicting the chemotherapeutic response of osteosarcoma. This method may have promising potential as a preoperative non-invasive modality.

show abstract

Section: Discussionmentioning

confidence: 94%

Section: Resultsmentioning

confidence: 99%

Value of diffusion-weighted imaging for evaluating chemotherapy response in osteosarcoma: A meta-analysis

Kubo

Furuta

Johan

et al. 2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…However, conventional chemotherapeutic agents not only elicit cell apoptosis, but also induce cell necrosis (27). Song et al (10) reported that following chemotherapy, the rate of tumor cell necrosis in control group tumors was increased by approximately 50%, regardless of tumor volume and location.…”

Section: Discussionmentioning

confidence: 99%

Necrosis of osteosarcoma cells induces the production and release of high‑mobility group box 1 protein

Yang

Wang

et al. 2017

Exp Ther Med

View full text Add to dashboard Cite

Abstract. Osteosarcoma is among the commonly observed malignancies worldwide. High-mobility group box 1 protein (HMGB1) is a highly conserved protein and is involved in the progression of various types of human cancer. The aim of the present study was to explore whether the level of HMGB1 was involved in the necrosis of osteosarcoma cells. Doxorubicin (DXR), as an inducer of necrosis, was administered to human osteosarcoma cell lines (MG63, Saos-2 and U2OS), and the results indicated that 0.5 µg/ml DXR significantly induced the necrosis of MG63 cells (P<0.01), while 0.5 and 1.0 µg/ml DXR suppressed the viability of MG63 and U2OS cells (P<0.05), relative to untreated controls. Additionally, treatment with DXR was observed by western blot analysis to markedly increase the expression levels of HMGB1 in MG63 cells, and to significantly increase the levels of secreted HMGB1 in the supernatants of MG63 and U2OS cells (P<0.01). In conclusion, cell necrosis increased the level of HMGB1 in osteosarcoma cells, as well as the level of secreted HMGB1 in cell supernatants. Therefore, HMGB1 may be a potential target in molecular therapy for patients with osteosarcoma.

show abstract

“…The current standard of chemotherapy response evaluation is to histologically assess the tumor necrosis of the excised lesion (2,3), which has been reported to be the most important prognostic factor in osteosarcoma after neoadjuvant chemotherapy (4). However, because tumor necrosis can be assessed only in the resected specimens after the completion of neoadjuvant chemotherapy, the continuation of ineffective chemotherapy can cause the development of resistant clones (3). To overcome these limitations, noninvasive imaging modalities including bone scintigraphy (5), CT (6), MR imaging (2,3,7,8), and 18 F-FDG PET (9)(10)(11) have been investigated to predict the effect of neoadjuvant chemotherapy.…”

mentioning

confidence: 99%

Combination of ¹⁸F-FDG PET/CT and Diffusion-Weighted MR Imaging as a Predictor of Histologic Response to Neoadjuvant Chemotherapy: Preliminary Results in Osteosarcoma

et al. 2013

View full text Add to dashboard Cite

We evaluated the potential of 18 F-FDG PET/CT and diffusionweighted imaging (DWI) to monitor the histologic response in patients with extremity osteosarcoma receiving neoadjuvant chemotherapy, using sequential PET/CT and MR imaging. Methods: We prospectively registered 28 patients with high-grade osteosarcoma treated with 2 cycles of neoadjuvant chemotherapy and surgery. All patients underwent sequential 18 F-FDG PET/CT and MR imaging before (PET/MR1) and after neoadjuvant chemotherapy (PET/MR2). Maximum standardized uptake value (SUV), tumor volume based on MR imaging (MRV), and the mean apparent diffusion coefficient (ADC) values were measured on PET/MR1 (SUV1, MRV1, and ADC1) and PET/MR2 (SUV2, MRV2, and ADC2). The percentage changes in maximum SUV (ΔSUV), MRV (ΔMRV), and ADC (ΔADC) were calculated, and the correlations among these parameters were evaluated. After surgery, the effects of neoadjuvant chemotherapy were graded histopathologically: grades III and IV (necrosis of $ 90%) indicated a good response, and grades I and II (necrosis of , 90%) indicated a poor response. The optimum cutoff values of ΔSUV, ΔMRV, ΔADC, and their combination for predicting histologic response were assessed by single-and multi-receiver-operating-characteristic curve analysis. Results: Twenty-seven patients were enrolled in the present study after 1 patient with inadequate acquisition of MR imaging was excluded. ΔSUV and ΔADC negatively correlated with each other (r 5 20.593, P 5 0.001), and ΔMRV did not correlate with ΔSUV or ΔADC. The cutoff value, sensitivity, specificity, and accuracy for predicting good histologic response were # 252%, 67%, 87%, and 78%, respectively, for ΔSUV and . 13%, 83%, 73%, and 78%, respectively, for ΔADC. However, ΔMRV did not predict histologic response. Sensitivity, specificity, and accuracy were 83%, 87%, and 85%, respectively, using the combined criterion of ΔSUV # 231% and ΔADC . 13%. Conclusion: In the current preliminary study, both PET/CT and DWI are useful for predicting histologic response after neoadjuvant chemotherapy in osteosarcoma. Combining PET/CT and DWI may be an effective method to predict the histologic response of patients to neoadjuvant chemotherapy.

show abstract

Role of MRI in osteosarcoma for evaluation and prediction of chemotherapy response: correlation with histological necrosis

Cited by 97 publications

References 31 publications

Value of diffusion-weighted imaging for evaluating chemotherapy response in osteosarcoma: A meta-analysis

Value of diffusion-weighted imaging for evaluating chemotherapy response in osteosarcoma: A meta-analysis

Necrosis of osteosarcoma cells induces the production and release of high‑mobility group box 1 protein

Combination of ¹⁸F-FDG PET/CT and Diffusion-Weighted MR Imaging as a Predictor of Histologic Response to Neoadjuvant Chemotherapy: Preliminary Results in Osteosarcoma

Contact Info

Product

Resources

About

Role of MRI in osteosarcoma for evaluation and prediction of chemotherapy response: correlation with histological necrosis

Cited by 97 publications

References 31 publications

Value of diffusion-weighted imaging for evaluating chemotherapy response in osteosarcoma: A meta-analysis

Value of diffusion-weighted imaging for evaluating chemotherapy response in osteosarcoma: A meta-analysis

Necrosis of osteosarcoma cells induces the production and release of high‑mobility group box 1 protein

Combination of 18F-FDG PET/CT and Diffusion-Weighted MR Imaging as a Predictor of Histologic Response to Neoadjuvant Chemotherapy: Preliminary Results in Osteosarcoma

Contact Info

Product

Resources

About

Combination of ¹⁸F-FDG PET/CT and Diffusion-Weighted MR Imaging as a Predictor of Histologic Response to Neoadjuvant Chemotherapy: Preliminary Results in Osteosarcoma